Advanced therapeutic and prophylactic strategies for Epstein-Barr virus infection in immunocompromised patients (Q36839720)

16 August 2017

1 reference

title

Advanced therapeutic and prophylactic strategies for Epstein-Barr virus infection in immunocompromised patients (English)

1 reference

16 August 2017

1 reference

Motohiko Okano

1

1 reference

16 August 2017

Thomas G Gross

series ordinal

2

1 reference

16 August 2017

publication date

1 June 2007

1 reference

Expert Review of Anti-infective Therapy

16 August 2017

published in

1 reference

16 August 2017

volume

5

1 reference

16 August 2017

issue

3

1 reference

16 August 2017

page(s)

403-413

1 reference

VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Relation of Burkitt's tumor-associated herpes-ytpe virus to infectious mononucleosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Seroepidemiologic studies of infectious mononucleosis with EB virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Precipitating antibody in human serum to an antigen present in cultured burkitt's lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

X-linked recessive progressive combined variable immunodeficiency (Duncan's disease)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Wiskott-Aldrich syndrome and Epstein-Barr virus-induced lymphoproliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Distinct clonotypic Epstein-Barr virus-induced fatal lymphoproliferative disorder in a patient with Wiskott-Aldrich syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Epstein Barr virus nuclear antigen positive lymphoma after cyclosporin A treatment in patient with renal allograft

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

The evolving therapeutic approaches for Epstein-Barr virus infection in immunocompetent and immunocompromised individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Epstein-Barr virus in patients with immunodeficiency disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Malignancy after transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

AIDS-associated non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Epstein-Barr virus-associated Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Epstein-barr virus nuclear antigen 1: from immunologically invisible to a promising T cell target

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Early events in Epstein-Barr virus infection of human B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

X-linked lymphoproliferative disease: twenty-five years after the discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

African Burkitt's lymphoma and an Epstein-Barr virus-enhancing plant Euphorbia tirucalli

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

SAP mediates specific cytotoxic T-cell functions in X-linked lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Interferon-gamma in a family with X-linked lymphoproliferative syndrome with acute Epstein-Barr virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Epstein-Barr virus-negative boys with non-Hodgkin lymphoma are mutated in the SH2D1A gene, as are patients with X-linked lymphoproliferative disease (XLP)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

A single ataxia telangiectasia gene with a product similar to PI-3 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Epstein-Barr virus-associated smooth muscle tumors in ataxia-telangiectasia: a case report and review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Isolation of a novel gene mutated in Wiskott-Aldrich syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Bone marrow transplantation in 26 patients with Wiskott-Aldrich syndrome from a single center

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Identification of the homologous beige and Chediak-Higashi syndrome genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Elevated antibody titers to Epstein-Barr virus and low natural killer cell activity in patients with Chediak-Higashi syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Epstein-Barr virus-associated T-cell lymphoma in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Regression of oral hairy leukoplakia after orally administered acyclovir therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Loss of circulating CD27+ memory B cells and CCR4+ T cells occurring in association with elevated EBV loads in XLP patients surviving primary EBV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Epstein-Barr virus-induced hemophagocytic lymphohistiocytosis and X-linked lymphoproliferative disease: a mimicker of sepsis in the pediatric intensive care unit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Detection of primary epstein-barr virus infection in a patient with x-linked lymphoproliferative disease receiving immunoglobulin prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Epstein-Barr virus vaccine: a cytotoxic T-cell-based approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Epstein–Barr Virus in Burkitt's Lymphoma and Nasopharyngeal Carcinoma: EBV DNA in Biopsies of Burkitt Tumours and Anaplastic Carcinomas of the Nasopharynx

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.3.403

21 January 2018

Identifiers

DOI

10.1586/14787210.5.3.403

1 reference

16 August 2017

1 reference